You are here: Industry Insights > STA

News List

WuXi STA Opens Its First Parental Formulation Manufacturing Line contractpharma
January 21, 2022
Features multiple filling modules and a built-in lyophilizer to fill vials, syringes, and cartridges, as well as to produce lyophilized powders.
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal En-CPhI.CN
October 15, 2019
Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients in Australia ...
WuXi STA Facilities Pass U.S. FDA Inspections contractpharma
July 25, 2019
Analytical Service Unit in Shanghai and API manufacturing facility in Changzhou successfully pass inspections.
WuXi STA Facilities Pass FDA Inspections contractpharma
July 24, 2019
No Form 483s were issued at Shanghai and Changzhou sites.
Phoenix Molecular, WuXi STA Reach Drug Supply Milestone contractpharma
June 10, 2019
Completes clinical trial supply to support Phase I/Ib study of PMD-026 for TNBC.
WuXi STA Enables Ascletis to Receive NDA Approval from China FDA for Ganovo contractpharma
June 19, 2018
STA Pharmaceutical, a subsidiary of WuXi AppTec, said that its partner, Ascletis has received approval from China Food and Drug Administration (CFDA) for its Category 1 new drug, Ganovo, also known as Danoprevir or ASC08, to treat viral hepatitis C.
WuXi STA plant gets FDA nod for 2 APIs, passing its first inspection fiercepharma
May 09, 2018
The solid-dose API operation of China’s WuXi had its first visit by FDA inspectors at a new plant in Changzhou, China, and the company says it aced it.
STA signs 5-year Supply Agreement with TESARO pharmaasia
August 08, 2017
STA has signed a 5-year Supply Agreement with TESARO.
WuXi's Pharmaceutical Development Services Division Merges with STA en-cphi.cn
July 31, 2017
STA Pharmaceutical Co., Ltd. (STA) announces that it has merged with WuXi AppTec's Pharmaceutical Development Services (PDS) division.
STA Pharmaceutical signs deal with Tesaro for zejula pharmaceutical-technology
July 27, 2017
STA Pharmaceutical, a US subsidiary of China-based company WuXi AppTec, has signed a new supply agreement with oncology-focused biopharmaceutical company Tesaro for certain starting and intermediate materials for zejula (niraparib).

Previous page 1 2 Next page